Past Work

For more than a decade, the Sabin PDP collaborated with partners from across the globe to develop new, low-cost vaccines that have little commercial market for diseases that primarily impact the world's poorest populations, including human hookworm, schistosomiasis, onchocerciasis, SARS and Chagas disease. Baylor College of Medicine and Texas Children’s Hospital Center for Vaccine Development continue this research as of May 2017.

Neglected tropical diseases (NTDs) are the most common affliction of the world’s poorest people. Thriving in communities that lack access to health services, adequate sanitation and clean water, NTDs blind, disable and disfigure, trapping families in a cycle of poverty and disease.

While investments in biomedical R&D have led to tremendous scientific breakthroughs and health improvements in the modern era, the benefits have been shared unevenly.

An estimated two billion people lack the medicines they need. The 2016 Access to Medicines Index analyzes pharmaceutical companies’ efforts to improve access to medicines, vaccines and diagnostics for low- and middle-income countries.

More than two billion people lack access to necessary medicines. High costs and limited health care infrastructure prevent many people from benefiting from recent medical advancements, leaving populations at risk of preventable diseases.

What the poor suffer from most happens in developed countries

While rarely talked about, Neglected Tropical Diseases are the most widespread ailment among the world's poorest of the poor – yet also ironically the most prevalent in top global economies, experts say.

Neglected Tropical Diseases (NTDs) are “the most important diseases you've never heard of. These are the most common afflictions of the world's poor,” Peter Hotez, MD, PhD, told CNA Nov. 11.

Catholic News Agency

Pope Francis, Sabin President Discuss Goals of the Catholic Church during Conference on Neglected Tropical Diseases

Vatican City – November 10, 2016 –Peter Hotez, M.D., Ph.D., president of the Sabin Vaccine Institute (Sabin) and director of the Sabin Product Development Partnership (Sabin PDP), today will help kick off the first-ever Vatican conference on neglected tropical diseases (NTDs) and rare diseases with a keynote address.

Sabin Vaccine Institute President Dr. Peter Hotez gave the keynote address on NTDs at the Pontifical Council for Health Care Workers’ XXXI International Conference, focused on NTDs and rare diseases.

Each year, the Sabin Vaccine Institute awards the Albert B. Sabin Gold Medal Award to an individual or small team that has made extraordinary contributions in the field of vaccinology or a complementary field.

Sabin PDP Begins Phase 1 Clinical Trial to Co-Administer Two Novel Hookworm Vaccine Candidates in Brazil

WASHINGTON, D.C. — April 28, 2016 — The Sabin Vaccine Institute (Sabin) today announced that its Product Development Partnership (Sabin PDP) began a Phase 1 clinical trial of Na-APR-1 (M74)/Alhydrogel® co-administered with Na-GST-1/Alhydrogel in Brazilian adults.

Pages

Subscribe to RSS - vaccine development